GSB Wealth Management LLC Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)

GSB Wealth Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 33.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,477 shares of the company’s stock after purchasing an additional 2,147 shares during the quarter. GSB Wealth Management LLC’s holdings in Zoetis were worth $1,656,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Quarry LP grew its position in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the last quarter. LRI Investments LLC purchased a new position in Zoetis in the first quarter worth $43,000. Fortitude Family Office LLC lifted its holdings in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. Central Valley Advisors LLC purchased a new stake in shares of Zoetis during the 2nd quarter worth $49,000. Finally, EdgeRock Capital LLC acquired a new position in shares of Zoetis during the 2nd quarter worth $56,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Price Performance

ZTS stock opened at $181.27 on Wednesday. The stock has a market capitalization of $82.12 billion, a price-to-earnings ratio of 34.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock’s fifty day simple moving average is $189.02 and its 200-day simple moving average is $178.25.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.41 EPS. Equities research analysts expect that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.